[Immunosuppressive therapy for idiopathic membranous glomerulopathy]

Area of Science:

• Nephrology
• Immunology

Background:

• Idiopathic membranous nephropathy (IMN) is the leading cause of nephrotic syndrome in adults.
• IMN has a natural course with frequent spontaneous remissions, but 50% of patients progress to end-stage renal disease.
• Corticosteroids alone are ineffective, while immunosuppressive drugs improve renal survival.

Purpose of the Study:

• To evaluate the efficacy and safety of immunosuppressive treatments for idiopathic membranous nephropathy.
• To identify criteria for selecting patients who would benefit most from immunosuppressive therapy.
• To compare the effectiveness of different immunosuppressive agents.

Main Methods:

• Review of existing literature on idiopathic membranous nephropathy treatment.
• Analysis of patient data regarding spontaneous remission rates and progression to end-stage renal disease.
• Comparison of treatment outcomes for corticosteroids, cyclophosphamide, and chlorambucil.

Main Results:

• Spontaneous remission occurs in a significant proportion of patients with IMN.
• Immunosuppressive therapy, particularly with cyclophosphamide, improves renal survival compared to corticosteroids alone.
• Cyclophosphamide is generally better tolerated and more efficacious than chlorambucil.

Conclusions:

• Immunosuppressive treatment for IMN should be reserved for patients with confirmed renal insufficiency due to spontaneous remission rates and treatment toxicity.
• Early identification of high-risk patients is crucial for optimizing the use of immunosuppressive therapy.
• Cyclophosphamide represents a preferred immunosuppressive option for eligible patients with IMN.